HOME >> BIOLOGY >> NEWS
Are we mice or men? Gene mutation linked to improving heart failure in mice proves lethal in humans

The goal of molecular medicine is to utilize the wealth of available experimental tools to develop treatments for human disease. Researchers develop animal models of a disease, investigate the underlying biological mechanisms, and conceive and test novel therapies until a successful treatment is found. The treatment strategy is then developed for human trial.

However, what if the outcome of the treatment was profoundly different in humans when compared with mice? Are we failing to consider the critical differences between mouse and man? Two studies published in the March 14 issue of the Journal of Clinical Investigation led by Evangelia Kranias and researchers at the University of Cincinnati reveal that a mutation in the human gene encoding the protein phospholamban (PLN) is linked to heart failure. In striking contrast to previous reports that indicate that "knock-out" or inhibition of PLN is beneficial in mouse models of heart failure, the researchers reveal that humans with mutated forms of PLN develop lethal heart failure.

Heart failure is a leading cause of human morbidity and mortality worldwide and costs close to $18 billion in health-carerelated costs in America each year. Characterized by suppressed calcium cycling in the heart, it impairs the ability of the heart to supply adequate oxygen- and nutrient-rich blood to the body. Calcium regulates the contraction and relaxation of heart muscle and PLN acts to halt calcium cycling at the end of the contraction so that muscles may relax between beats.

Recent experimental successes in mice have generated much enthusiasm for treating an array of conditions that ultimately result in heart failure by "knocking-out" the PLN gene and thereby enhancing calcium cycling.

However, the effect of inhibiting PLN in cases of cardiac hypertrophy (which can progress to heart failure) was unknown.

In the first study, the researchers studied two mouse models of c
'"/>

Contact: Brooke Grindlinger
science_editor@the-jci.org
212-342-9006
Journal of Clinical Investigation
10-Mar-2003


Page: 1 2 3

Related biology news :

1. Genetic mutations linked to the practice of burning coal in homes in China
2. Spontaneous mutation produces new MAO A/B knockout mouse
3. How an insidious mutation fools DNA replication
4. Using statistics to decipher secrets of natural mutation
5. Rare mutations can significantly increase risk factor for heart disease
6. Genetic mutation linked to more aggressive breast cancer found more often in African-Americans
7. LBP-1a gene mutation linked to disruption of normal fetal development
8. Genetic mutation found that is major contributor to type 1 diabetes
9. The mother lode of mutations
10. Gene mutation causes progressive changes to cell structure in children with Progeria
11. Single gene mutation muddying Parkinsons risk forecasts

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/6/2017)... 2017 Mintigo , the leader ... Predictive Sales Coach TM , its new artificial ... into Salesforce. This unique AI application will allow ... with deep knowledge of their customers and prospects ... Predictive Sales Coach extends Mintigo,s existing customer success ...
(Date:3/2/2017)... 2, 2017 Who risk to be deprived ... the full report: https://www.reportbuyer.com/product/4313699/ WILL APPLE ... FIELD? Fingerprint sensors using capacitive technology represent a ... vendor Idex forecasts an increase of 360% of the ... of the fingerprint sensor market between 2014 and 2017 ...
(Date:2/28/2017)... ANGELES , Feb. 28, 2017   Acuant ... verification software globally, announces significant enhancements to new and ... May 2016. New products include mobile and desktop Acuant ... DocX TM - a real time manual review ... core idScanĀ® technology provides the fastest and most accurate ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... , March 23, 2017 Kineta, Inc., ... of novel therapies in immuno-oncology, today announced the ... small molecule compounds that activate interferon response factor ... and demonstrate immune-mediated tumor regression in a murine ... study who demonstrated complete tumor regression to initial ...
(Date:3/23/2017)... March 23, 2017 In today,s ... equities in the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: ... (NYSE MKT: SYN), and Regulus Therapeutics Inc. (NASDAQ: ... 2017, Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market ... free report at: ...
(Date:3/22/2017)... March 22, 2017  Ascendis Pharma A/S (Nasdaq: ... TransCon technology to address significant unmet medical needs ... the full year ended December 31, 2016. ... our company as we broadened our pipeline and ... rare disease company with an initial focus on ...
(Date:3/22/2017)... LEXINGTON, Mass. , March 22, 2017   ... collections, today announced that Doctors Pathology Service ... mid-Atlantic region of the United States ... the Delaware Health Information Network (DHIN) to ... researchers. The novel program, announced in ...
Breaking Biology Technology:
Cached News: